Strategies such as synthetic lethality and the development of small-molecule inhibitors show encouraging signs that BRG1 can be successfully targeted through therapeutic intervention, and CRISPR/Cas9 gene editing is emerging as a novel strategy; all with the potential to act as adjuvant therapy to improve current standard treatments for brain cancer. This evidence concerns the gene SMARCA4 and brain cancer.